secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-067026
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q4 rev $23.8M (-4% YoY); FY2025 rev $85.3M (-6%); guides FY2026 $80-85M
--------------------------------------------------------------------------------

- Q4 2025 net income from continuing ops $13.9M (includes $38.4M deferred tax release) vs net loss $27.2M YoY.
- Full-year 2025 net loss $58.8M vs $90.9M; adjusted EBITDA loss $62.6M vs $64.2M.
- FY2026 revenue guidance $80-85M; company expects seasonality similar to prior years.
- Cash and investments from continuing ops $210.7M at Dec 31, 2025; ~$550M after SomaLogic close on Jan 30, 2026.
- Approximately $1 billion in U.S. federal NOL carryforwards available; usage may be limited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526067026/0001193125-26-067026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526067026/lab-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-067026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer